A five year nationwide retrospective study assessing of central nervous system complications in patients treated with Immune checkpoint inhibitors
Latest Information Update: 06 Jul 2020
Price :
$35 *
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Bladder cancer; Hodgkin's disease; Liposarcoma; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Renal cancer; Small cell lung cancer
- Focus Adverse reactions
- 06 Jul 2020 New trial record
- 26 May 2020 Results presented at the 6th Congress of the European Academy of Neurology